Below are several journal articles to provide relevant evidence-based information about the management of IBD
  • Chauhan, U., Stitt, L., Rohatinsky, N., Watson, M., Currie, B., Westin, L., ... & Nistor, I. (2022). Patients’ Access to Telephone and E-mail Services Provided by IBD Nurses in Canada. Journal of the Canadian Association of Gastroenterology, 5(3), 129-136.
  • Roda, G., Chien Ng, S., Kotze, P. G., Argollo, M., Panaccione, R., Spinelli, A., ... & Danese, S. (2020). Crohn’s disease. Nature Reviews Disease Primers, 6(1), 1-19. (Subscription required)

    Mayo Clinic (2019) Ulcerative Colitis. (PDF)

    Gajendran, M., Loganathan, P., Catinella, A. P., & Hashash, J. G. (2018). A comprehensive review and update on Crohn's disease. Disease-a-month, 64(2), 20-57.

    Gallo, G., Kotze, P. G., & Spinelli, A. (2018). Surgery in ulcerative colitis: When? How? Best practice & research. Clinical gastroenterology, 32, 71-78. (Subscription required)
  • Gonczi, L., Bessissow, T., & Lakatos, P. L. (2019). Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?. World journal of gastroenterology, 25(41), 6172. doi: 10.3748/wjg.v25.i41.6172

    Rodrigues, B. L., Mazzaro, M. C., Nagasako, C. K., Ayrizono, M. D. L. S., Fagundes, J. J., & Leal, R. F. (2020). Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World Journal of Gastrointestinal Endoscopy, 12(12), 504. doi: 10.4253/wjge.v12.i12.504

    Walsh, A. J., Bryant, R. V., & Travis, S. P. (2016). Current best practice for disease activity assessment in IBD. Nature reviews Gastroenterology & hepatology, 13(10), (Subscription may be required) 
  • Review on current and novel treatment for IBD
    Abbass, M., Cepek, J., Parker, C. E., Nguyen, T. M., MacDonald, J. K., Feagan, B. G., ... & Jairath, V. (2019). Adalimumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews, (11).

    Na, S. Y., & Moon, W. (2019). Perspectives on current and novel treatments for inflammatory bowel disease. Gut and Liver, 13(6), 604. doi: 10.5009/gnl19019

    Challenges in maintaining long-term remission
    Ashton, J. J., Green, Z., Kolimarala, V., & Beattie, R. M. (2019). Inflammatory bowel disease: Long-term therapeutic challenges. Expert Review of Gastroenterology & Hepatology, 13(11), 1049-1063. (Subscription may be required)

    Review of strategies to treat to target
    Colombel, J. F., D’haens, G., Lee, W. J., Petersson, J., & Panaccione, R. (2020). Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. Journal of Crohn's and Colitis, 14(2), 254-266.

    Anemia and iron therapy in IBD 
    Kumar, A., & Brookes, M. J. (2020). Iron therapy in inflammatory bowel disease. Nutrients, 12(11), 3478.

    Patel, D., Trivedi, C., & Khan, N. (2018). Management of anemia in patients with inflammatory bowel disease (IBD). Current treatment options in gastroenterology, 16(1), 112-128. (Subscription may be required)

    Strategies to manage perianal disease
    Nguyen, G. C. (2018). The Bottom Line: A Multidisciplinary Approach Is Key to Treating Perianal Fistulizing Crohn’s Disease. Journal of the Canadian Association of Gastroenterology, 1(4), 139.

    Treat to target strategies and review on STRIDE-II
    Turner, D., Ricciuto, A., Lewis, A., D’amico, F., Dhaliwal, J., Griffiths, A. M., ... & Dignass, A. (2021). STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology, 160(5), 1570-1583.

    Practical guide for thiopurine monitoring in IBD.  
    Warner, B., Johnston, E., Arenas-Hernandez, M., Marinaki, A., Irving, P., & Sanderson, J. (2018). A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterology, 9(1), 10-15.
  • Singh, S., Picardo, S., & Seow, C. H. (2020). Management of inflammatory bowel diseases in special populations: obese, old, or obstetric. Clinical Gastroenterology and Hepatology, 18(6), 1367-1380. (Subscription may be required)
  • Leddin, D., Lieberman, D. A., Tse, F., Barkun, A. N., Abou-Setta, A. M., Marshall, J. K., ... & Leontiadis, G. I. (2018). Clinical practice guideline on screening for colorectal cancer in individuals with a family history of nonhereditary colorectal cancer or adenoma: the Canadian Association of Gastroenterology Banff Consensus. Gastroenterology, 155(5), 1325-1347. doi: org/10.1053/j.gastro.2018.08.017

    Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017). ACG clinical guideline: preventive care in inflammatory bowel disease. Official journal of the American College of Gastroenterology| ACG, 112(2), 241-258. doi: 10.1038/ajg.2016.537

    Abegunde, A. T., Muhammad, B. H., & Ali, T. (2016). Preventive health measures in inflammatory bowel disease. World journal of gastroenterology, 22(34), 7625. doi: 10.3748/wjg.v22.i34.7625
  • Sadowski, D. C., Camilleri, M., Chey, W. D., Leontiadis, G. I., Marshall, J. K., Shaffer, E. A., ... & Walters, J. R. (2020). Canadian Association of Gastroenterology clinical practice guideline on the management of bile acid diarrhea. Journal of the Canadian Association of Gastroenterology, 3(1), e10-e27.

    Vítek, L. (2015). Bile acid malabsorption in inflammatory bowel disease. Inflammatory bowel
    diseases, 21(2), 476-483.
  • Click, B. & Regueiro, M. Managing risks with biologics. Current Gastroenterology Reports 21.1 (2019): 1-11. (Subscription may be required)

    Quezada, S. M., McLean, L. P., & Cross, R. K. (2018). Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology, 12(12), 1183-1191. (Subscription may be required)
  • Nistor, O. I., Godfrey, C., Ross-White, A., & Wilson, R. (2022). Systematic Review and Meta-analysis on the Incidence, Prevalence and Determinants of Discomfort in Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 5(2), 96-97.
  • Bernstein, C. N., Benchimol, E. I., Bitton, A., Murthy, S. K., Nguyen, G. C., Lee, K., ... & Kaplan, G. G. (2019). The impact of inflammatory bowel disease in Canada 2018: Extra-intestinal diseases in IBD. Journal of the Canadian Association of Gastroenterology, 2(Supplement_1), S73-S80.

    Garber, A., & Regueiro, M. (2019). Extraintestinal manifestations of inflammatory bowel disease: epidemiology, etiopathogenesis, and management. Current gastroenterology reports, 21(7), 1-13.

    Yokoda, R. T., & Carey, E. J. (2019). Primary biliary cholangitis and primary sclerosing cholangitis. Official journal of the American College of Gastroenterology| ACG, 114(10), 1593-1605. doi: 10.14309/ajg.0000000000000268 (Subpscription may be required)
  • Dubinsky, M. C., Dotan, I., Rubin, D. T., Bernauer, M., Patel, D., Cheung, R., ... & Keefer, L. (2021). Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert review of gastroenterology & hepatology, 15(9), 985-997.

    Graff, L. A., Fowler, S., Jones, J. L., Benchimol, E. I., Bitton, A., Huang, J. G., ... & Bernstein, C. N. (2021). Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. Journal of the Canadian Association of Gastroenterology, 4(Supplement_2), S46-S53.

    Qazi, T. (2020). Fatigue in inflammatory bowel disease: A problematic ailment. Current Opinion in Gastroenterology, 36(4), 284-294. (Subscription may be required)
  • Ghishan, F. K., & Kiela, P. R. (2017). Vitamins and minerals in inflammatory bowel disease. Gastroenterology Clinics, 46(4), 797-808. (Subscription may be required)

    Green, N., Miller, T., Suskind, D., & Lee, D. (2019). A review of dietary therapy for IBD and a vision for the future. Nutrients, 11(5), 947.

    Gu, P., & Feagins, L. A. (2020). Dining with inflammatory bowel disease: a review of the literature on diet in the pathogenesis and management of IBD. Inflammatory Bowel Diseases, 26(2), 181-191.

    Li, S., Ney, M., Eslamparast, T., Vandermeer, B., Ismond, K. P., Kroeker, K., ... & Tandon, P. (2019). Systematic review of nutrition screening and assessment in inflammatory bowel disease. World journal of gastroenterology, 25(28), 3823. doi:10.3748/wjg.v25.i28.3823

    Mentella, M. C., Scaldaferri, F., Pizzoferrato, M., Gasbarrini, A., & Miggiano, G. A. D. (2020). Nutrition, IBD and gut microbiota: a review. Nutrients, 12(4), 944.

    Picardo, S., Altuwaijri, M., Devlin, S. M., & Seow, C. H. (2020). Complementary and alternative medications in the management of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 13, 1756284820927550.

    Weber, A. T., Shah, N. D., Sauk, J., & Limketkai, B. N. (2019). Popular diet trends for inflammatory bowel diseases: claims and evidence. Current Treatment Options in Gastroenterology, 17(4), 564-576. (Subscription may be required)
  • Ananthakrishnan, A. N., Martin, C., Kane, S., Sandler, R. S., & Long, M. D. (2019). Paternal disease activity is associated with difficulty in conception among men with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology, 17(1), 203-204. 

    Leenhardt, R., Rivière, P., Papazian, P., Nion-Larmurier, I., Girard, G., Laharie, D., & Marteau, P. (2019). Sexual health and fertility for individuals with inflammatory bowel disease. World Journal of Gastroenterology, 25(36), 5423. doi: 10.3748/wjg.v25.i36.5423

    Management of IBD during pregnancy
    Nguyen, G. C., Seow, C. H., Maxwell, C., Huang, V., Leung, Y., Jones, J., ... & Paterson, W. (2016). The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology, 150(3), 734-757.

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest